Navigation Links
Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms
Date:3/31/2008

At two years, Company's TAXUS(R) and PROMUS(TM) Stents demonstrate positive

and similar outcomes

NATICK, Mass. and CHICAGO, March 31 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed positive two-year results from Abbott's prospective, randomized (3:1), single blind, non-inferiority SPIRIT II Trial comparing the safety and efficacy of the XIENCE(TM) V (PROMUS(TM)) Everolimus-Eluting Coronary Stent and Boston Scientific's worldwide market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System ("TAXUS Stent") in 300 patients in Europe. The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. Boston Scientific is the only company offering two distinct drugs on two deliverable platforms - the TAXUS and PROMUS Stents. The results were presented today at the SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago by Professor Patrick Serruys, M.D., Ph.D., Chief of Interventional Cardiology, Thoraxcenter-Erasmus University Rotterdam, The Netherlands, and the SPIRIT II Principal Investigator.

At two years, results from the SPIRIT II trial demonstrated no numerical difference between the XIENCE V (PROMUS) Stent and the TAXUS Stent in their angiographic outcomes, nor were there statistically significant differences in the clinical outcomes. The cardiac death rate for the XIENCE V (PROMUS) Stent was 0.5 percent and for the TAXUS Stent was 1.4 percent (p=0.45). Myocardial infarction (MI) rates for the XIENCE V (PROMUS) Stent and the TAXUS Stent were 2.8 percent and 5.5 percent (p=0.29), respectively. Ischemia-driven target lesion revascularization (
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
3. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
4. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
9. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
10. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
11. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Decision Resources Group finds that by ... to be worth $2 billion (U.S. dollars), increasing at a ... five years (to 2018). This growth comes as ... 2013 and 4.9 percent expected over the next three to ... small but highly competitive. The pharmaceutical market is dominated by ...
(Date:9/22/2014)... YORK , September 22, 2014 ... Market Report on "Global Market Study on Ophthalmic Devices: ... by 2020," the global ophthalmic devices market was valued at USD ... at a CAGR of 6.5% from 2014 to 2020, ... in 2020. Browse the full Global Market Study ...
(Date:9/22/2014)... -- AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ), a ... announced today that they are starting production of the ... is designed for placement inside optical shops and Eye ... there are over 20,000 optical stores in America.  ... first automated kiosk dedicated to cleaning and sanitizing eyeglasses ...
Breaking Medicine Technology:Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2
... MARY, Fla., Jan. 26, 2012   In a pediatric ... caring environment, Middleton Pediatrics is one of the first ... to assess their young patients vision.  This revolutionary vision ... important vision data in one second or less.  ...
... 26, 2012  Aria Diagnostics, a molecular diagnostics company, ... study that examines the accuracy of its non-invasive ... (associated with Down syndrome) and Trisomy 18 (associated ... test, coupled with a proprietary algorithm to assess ...
Cached Medicine Technology:Middleton Pediatrics Now Using Spot to Screen Patients 2Middleton Pediatrics Now Using Spot to Screen Patients 3Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Aria's Technology 2
(Date:9/22/2014)... RI (PRWEB) September 22, 2014 Severe weather can ... of time. That’s why, as part of National Preparedness Month, ... and your family prepare for the unexpected:, , ... well as nonperishable food and one gallon of water per person ... Create an evacuation plan that includes pets so your family ...
(Date:9/22/2014)... / Westchester County, NY (PRWEB) September 22, 2014 ... (NYGPS) has joined the Department of Surgery at the ... named Mount Sinai Doctors New York Group for Plastic ... lower Hudson Valley access to a team of world-renowned ... techniques. Additionally, C. Andrew Salzberg, MD, who led ...
(Date:9/22/2014)... Metformin, a drug commonly used to treat diabetes, may ... (TSH) among patients with an underactive thyroid, a new ... levels may be associated with heart problems and broken ... this study. Among those in the study with ... low levels of thyroid-stimulating hormone per year compared with ...
(Date:9/22/2014)... The report segments the global physiotherapy equipment ... The equipment segment accounted for a lion’s share ... However, the accessories segment is expected to grow ... owing to the rising demand of physiotherapy services ... are the fastest-growing segments in the physiotherapy equipment ...
(Date:9/22/2014)... critical information systems, such as medical records in ... new approach to computer security that authenticates users ... automatically logs them out when they leave or ... terminal. , Dartmouth,s Trustworthy Health and Wellness ... at the IEEE Symposium on Security & ...
Breaking Medicine News(10 mins):Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 5Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 3
... Patient Satisfaction Scores Through Implementing the RROHC Bundle of ... Feb. 27 -- Hansten Healthcare PLLC , a ... and skill development and improving patient satisfaction scores, today ... company as faculty and RROHC Master Coach. , ...
... LAS VEGAS, Feb. 27 Orthopaedic surgeon David ... Specialty Societies (BOS), of the American Academy of Orthopaedic ... Meeting. Dr. Polly will also sit on the Academy,s ... in the Department of Orthopaedic Surgery at the University ...
... United States have used yeast and mammalian cells to ... Parkinson,s disease. , Yeasts are single cell organisms, ... that of cells found in animals and humans. Yeasts ... and offer the ability to screen or test thousands ...
... Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) ... procedure pursuant to Law 223/1991 concerning its Bresso, Italy, ... total of 62 employees. Within 75 days of ... Trade Unions, will review solutions that may reduce the ...
... shares poetry author,s two-year period of severe depressionBROOKLYN, N.Y., ... Arthur F. Temple kept a journal, in which the ... had become intolerable, and the result is this fascinating ... ).In nearly 100 poems, Temple shares his heartfelt feelings ...
... Driven by Demand for Branded Products- Adjusted Diluted EPS ... 2009 Adjusted EPS Guidance Range of $2.59 - $2.67CHADDS ... ENDP ) today reported double-digit percentage growth in ... the fourth quarter and full year ended December 31, ...
Cached Medicine News:Health News:Relationship and Results Oriented Healthcare Announces New Faculty With Impressive Patient Satisfaction Scores 2Health News:David W. Polly Jr., MD, Elected Secretary of Academy Board of Specialty Societies 2Health News:How yeast is helping us to understand Parkinson's Disease 2Health News:How yeast is helping us to understand Parkinson's Disease 3Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 2Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 3Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 4Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 5Health News:Journey into the Dark Recesses of the Subconscious Mind 2Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 2Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 3Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 4Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 5Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 6Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 7Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 8Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 9Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 10Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 11Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 12Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 13Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 14
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With reinforced nylon ...
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With reinforced nylon ...
... concave seats and large backrests with lumbar ... armrests, and casters and glides. • Choose ... a variety of environments including: industry, education, ... and office. • With reinforced nylon base ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With cast ...
Medicine Products: